Table 1.

Prevalence of endoscopic remission or mildly active disease (MES 0/1) by patient-reported outcomes in clinical trials of biologic agents and tofacitinib for moderate-severe ulcerative colitis, post-induction therapy (6–8 weeks) and during maintenance therapy (week 30–54)

PRO measure	INDUCTION (ACT-1/2, PURSUIT, OCTAVE-1/2, GEMINI1, MLN002)	MAINTENANCE (ACT-1/2, GEMINI1, OCTAVE-Sustain)
RBS 0 + SFS 0/1	75.3% (73.0–77.5), 1120/1471	87.6% (84.9–89.9), 592/673
RBS 0 + SFS 0	81.2% (77.7–84.3), 515/618	90.7% (87.3–93.2), 372/407
RBS 0 + SFS 2/3	34.5% (30.5–38.7), 181/535	44.6% (35.0–54.6), 45/101
RBS 0	64.3% (62.2–66.4), 1299/2006	82.0% (79.2–84.6), 637/774
RBS 0/1	48.9% (46.9.0–50.9), 1229/2531	73.5% (70.6–76.3), 675/916
RBS 2/3 + SFS 2/3	9.8% (7.5–12.6), 53/580	14.5% (7.8–25.4), 9/88

RBS: rectal bleeding score; SFS: stool frequency score; PRO: patient reported outcome